You are here: Industry Insights > teva

News List

Teva launches generic AndroGel biospectrumasia
April 22, 2019
Testosterone Gel 1.62% CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone
FDA grants final approval for Teva's generic nasal spray formulation of opioid overdose reversal drug naloxone hydrochloride firstwordpharma
April 21, 2019
Teva received final FDA approval for its nasal spray formulation of generic naloxone hydrochloride to stop or reverse the effects of an opioid overdose, the agency announced Friday.
Recro, Teva Extend License and Supply Agreement contractpharma
April 18, 2019
Recro Gainesville, the contract development and manufacturing organization (CDMO) division of Recro Pharma, has amended its existing license and supply agreement with ...
Teva CEO Kåre Schultz nabs whopping $33M in first…… fiercepharma
April 18, 2019
If you thought Teva had gone big-time with its 2017 pay package for CEO Kåre Schultz, check out what it paid him in 2018.
Teva announces launch of generic version of EXJADE® biospectrumasia
March 26, 2019
Deferasirox Tablets for Oral Suspension are indicated for the treatment of chronic iron overload due to blood transfusions
Novo Nordisk settles Victoza patent dispute with Teva in US pharmaceutical-technology
March 20, 2019
Available in pre filled pens, Victoza is indicated to improve glycemic control in type 2 diabetes. Credit: Novo Nordisk A/S.
Teva plant tagged with warning letter for issues making schizophrenia drug fiercepharma
March 08, 2019
For years now, Teva has had difficulty with the laser drilling of a schizophrenia drug so that patients get the right dose. The FDA, having finally tired of the company being unable to resolve the issues, has now slapped the plant in Florida with a warnin
Rebounding Teva is ‘too cheap to ignore,' upbeat analysts say fiercepharma
February 24, 2019
What kind of difference can one year make? Just ask some Teva analysts, who these days seem upbeat that the Israeli drugmaker's cost-cutting measures are paying off.
Teva forecasts worse-than-expected ‘trough year’ as generics hammer MS drug Copaxone fiercepharma
February 24, 2019
Shares of Teva fell nearly 12% in pre-market trading to $16.80 after the company’s executives conceded during the fourth-quarter earnings report that 2019 would be an even tougher year than analysts had been expecting.
Teva, FTC enter expanded settlement barring certain 'pay-for-delay' deals for 10 years fiercepharma
February 24, 2019
Teva has already had to pony up $1.2 billion to the federal government for a "pay-for-delay" deal to protect narcolepsy drug Provigil. But now the government says that settlement didn't go far enough, and the parties returned with an expanded arrangement

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page